Literature DB >> 24493855

A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.

Emmanuel Griessinger1, Fernando Anjos-Afonso, Irene Pizzitola, Kevin Rouault-Pierre, Jacques Vargaftig, David Taussig, John Gribben, François Lassailly, Dominique Bonnet.   

Abstract

Acute myeloid leukemia-initiating cells (LICs) are responsible for the emergence of leukemia and relapse after chemotherapy. Despite their identification more than 15 years ago, our understanding of the mechanisms responsible for their self-renewal activity and their chemoresistance remains poor. The slow progress in this area is partly due to the difficulty of studying these cells ex vivo. Indeed, current studies are reliant on xenotransplantation assays in immunodeficient mice. In this paper, we report that by modeling key elements of the bone marrow niche using different stromal feeder layers and hypoxic culture conditions, we can maintain LICs over at least 3 weeks and support their self-renewal properties demonstrated through primary and secondary successful xenograft. We provide a proof of principle that this niche-like culture system can be used to study LIC chemoresistance following in vitro cytarabine treatment similarly to the xenograft chemotherapy model. We found that although LICs are believed to be more chemoresistant than non-LICs, functionally defined LICs are not enriched after cytarabine treatment, and heterogeneity in their resistance to treatment can be seen between patients and even within the same patient. We present a culture system that can be used as an in vitro surrogate for xenotransplantation and that has the potential to dramatically increase the throughput of the investigation of LICs. This would further provide the means by which to identify and target the functionality of the different signaling pathways involved in the maintenance and resistance of LICs to improve acute myeloid leukemia treatments.

Entities:  

Keywords:  Acute myeloid leukemia; Leukemia initiating cells; Leukemic long-term culture initiating cell; Xenograft

Mesh:

Substances:

Year:  2014        PMID: 24493855      PMCID: PMC3973718          DOI: 10.5966/sctm.2013-0166

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  40 in total

1.  Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).

Authors:  Yinghui Guan; Brigitte Gerhard; Donna E Hogge
Journal:  Blood       Date:  2002-12-05       Impact factor: 22.113

2.  Homing and engraftment defects in ex vivo expanded murine hematopoietic cells are associated with downregulation of beta1 integrin.

Authors:  S J Szilvassy; T E Meyerrose; P L Ragland; B Grimes
Journal:  Exp Hematol       Date:  2001-12       Impact factor: 3.084

3.  Expansion of human SCID-repopulating cells under hypoxic conditions.

Authors:  Guénahel H Danet; Yi Pan; Jennifer L Luongo; Dominique A Bonnet; M Celeste Simon
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

4.  Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts.

Authors:  Øystein Bruserud; Anita Ryningen; Line Wergeland; Nils Idar Glenjen; Bjørn Tore Gjertsen
Journal:  Haematologica       Date:  2004-04       Impact factor: 9.941

5.  Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.

Authors:  K M Ardeshna; P Smith; A Norton; B W Hancock; P J Hoskin; K A MacLennan; R E Marcus; A Jelliffe; G Vaughan; D C Linch
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

6.  AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.

Authors:  Mark Wunderlich; Benjamin Mizukawa; Fu-Sheng Chou; Christina Sexton; Mahesh Shrestha; Yogen Saunthararajah; James C Mulloy
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

7.  Identification of the haematopoietic stem cell niche and control of the niche size.

Authors:  Jiwang Zhang; Chao Niu; Ling Ye; Haiyang Huang; Xi He; Wei-Gang Tong; Jason Ross; Jeff Haug; Teri Johnson; Jian Q Feng; Stephen Harris; Leanne M Wiedemann; Yuji Mishina; Linheng Li
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

8.  Osteoblastic cells regulate the haematopoietic stem cell niche.

Authors:  L M Calvi; G B Adams; K W Weibrecht; J M Weber; D P Olson; M C Knight; R P Martin; E Schipani; P Divieti; F R Bringhurst; L A Milner; H M Kronenberg; D T Scadden
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

9.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

Authors:  Katrina M Comerford; Timothy J Wallace; Jörn Karhausen; Nancy A Louis; Michael C Montalto; Sean P Colgan
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.

Authors:  Janine T Erler; Christopher J Cawthorne; Kaye J Williams; Marianne Koritzinsky; Bradley G Wouters; Clare Wilson; Crispin Miller; Costas Demonacos; Ian J Stratford; Caroline Dive
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

View more
  37 in total

Review 1.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

2.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

3.  Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Authors:  Nikolas Herold; Sean G Rudd; Linda Ljungblad; Kumar Sanjiv; Ida Hed Myrberg; Cynthia B J Paulin; Yaser Heshmati; Anna Hagenkort; Juliane Kutzner; Brent D G Page; José M Calderón-Montaño; Olga Loseva; Ann-Sofie Jemth; Lorenzo Bulli; Hanna Axelsson; Bianca Tesi; Nicholas C K Valerie; Andreas Höglund; Julia Bladh; Elisée Wiita; Mikael Sundin; Michael Uhlin; Georgios Rassidakis; Mats Heyman; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Julian Walfridsson; Sören Lehmann; Dan Grandér; Thomas Lundbäck; Per Kogner; Jan-Inge Henter; Thomas Helleday; Torsten Schaller
Journal:  Nat Med       Date:  2017-01-09       Impact factor: 53.440

Review 4.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 5.  Metabolic underpinnings of leukemia pathology and treatment.

Authors:  Travis Nemkov; Angelo D'Alessandro; Julie A Reisz
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-07

6.  Can systems biology approach help in finding more effective treatment for acute myeloid leukemia?

Authors:  Anuradha Vaidya
Journal:  Syst Synth Biol       Date:  2014-04-16

7.  Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Authors:  Thomas Farge; Estelle Saland; Fabienne de Toni; Nesrine Aroua; Mohsen Hosseini; Robin Perry; Claudie Bosc; Mayumi Sugita; Lucille Stuani; Marine Fraisse; Sarah Scotland; Clément Larrue; Héléna Boutzen; Virginie Féliu; Marie-Laure Nicolau-Travers; Stéphanie Cassant-Sourdy; Nicolas Broin; Marion David; Nizar Serhan; Audrey Sarry; Suzanne Tavitian; Tony Kaoma; Laurent Vallar; Jason Iacovoni; Laetitia K Linares; Camille Montersino; Rémy Castellano; Emmanuel Griessinger; Yves Collette; Olivier Duchamp; Yara Barreira; Pierre Hirsch; Tony Palama; Lara Gales; François Delhommeau; Barbara H Garmy-Susini; Jean-Charles Portais; François Vergez; Mary Selak; Gwenn Danet-Desnoyers; Martin Carroll; Christian Récher; Jean-Emmanuel Sarry
Journal:  Cancer Discov       Date:  2017-04-17       Impact factor: 39.397

Review 8.  Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.

Authors:  Aline Renneville; Mrinal M Patnaik; Onyee Chan; Eric Padron; Eric Solary
Journal:  Leukemia       Date:  2021-06-26       Impact factor: 11.528

9.  Alginate foam-based three-dimensional culture to investigate drug sensitivity in primary leukaemia cells.

Authors:  Mahroo Karimpoor; Eva Yebra-Fernandez; Maryam Parhizkar; Mine Orlu; Duncan Craig; Jamshid S Khorashad; Mohan Edirisinghe
Journal:  J R Soc Interface       Date:  2018-04       Impact factor: 4.118

10.  Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis.

Authors:  Kaitlyn M Dykstra; Hannah R S Fay; Ashish C Massey; Neng Yang; Matthew Johnson; Scott Portwood; Monica L Guzman; Eunice S Wang
Journal:  Blood Adv       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.